These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10609271)

  • 1. [Hepatitis C: natural history, biology, treatment monitoring].
    Poynard T
    Pathol Biol (Paris); 1999 Nov; 47(9):911-6. PubMed ID: 10609271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Retreatment of patients with chronic hepatitis C].
    Ostojić R
    Acta Med Croatica; 2005; 59(5):447-51. PubMed ID: 16381242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
    Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
    J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment and prevention of hepatitis C].
    Poynard T; Ratziu V; Benhamou Y; Regimbeau C
    Rev Prat; 2000 May; 50(10):1100-7. PubMed ID: 10905096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribavirin in the treatment of hepatitis C.
    Abonyi ME; Lakatos PL
    Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of chronic hepatitis C.
    Asselah T; Boyer N; Ripault MP; Martinot M; Marcellin P
    Minerva Gastroenterol Dietol; 2007 Mar; 53(1):9-23. PubMed ID: 17415342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of hepatitis C and the impact of anti-viral therapy.
    Boyer N; Marcellin P
    Forum (Genova); 2000; 10(1):4-18. PubMed ID: 10717254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India.
    Hissar SS; Kumar M; Tyagi P; Goyal A; Suneetha PV; Agarwal S; Rastogi A; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2009 Apr; 24(4):581-7. PubMed ID: 19032460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: predicting response in hepatitis C virus therapy.
    Mihm U; Herrmann E; Sarrazin C; Zeuzem S
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1043-54. PubMed ID: 16611264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of combination therapy with interferon-alpha and ribavirin for chronic hepatitis C in relation to liver fibrosis and serum aminotransferase activity].
    Karpińska E; Wawrzynowicz-Syczewska M; Jurczyk K; Morańska I; Urbanowicz W; Boroń-Kaczmarska A
    Wiad Lek; 2005; 58(11-12):616-21. PubMed ID: 16594470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological response to interferon alfa-based therapies in hepatitis C.
    Lee SS
    Semin Liver Dis; 2004; 24 Suppl 2():55-60. PubMed ID: 15346247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interferon-alpha and liver fibrosis in patients with chronic damage due to hepatitis C virus].
    Gonzalez-Huezo MS; Gallegos-Orozco JF
    Rev Gastroenterol Mex; 2003; 68(3):239-44. PubMed ID: 14702938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation.
    Mindikoglu AL; Regev A; Casanova-Romero PY; Bejarano PA; Martinez EJ; Tzakis AG; Schiff ER
    Transplant Proc; 2006 Jun; 38(5):1440-4. PubMed ID: 16797327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
    Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
    Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation.
    Giostra E; Kullak-Ublick GA; Keller W; Fried R; Vanlemmens C; Kraehenbuhl S; Locher S; Egger HP; Clavien PA; Hadengue A; Mentha G; Morel P; Negro F
    Transpl Int; 2004 May; 17(4):169-76. PubMed ID: 15060764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon and ribavirin combination therapy: indications and schedules.
    Weiland O
    Forum (Genova); 2000; 10(1):22-8. PubMed ID: 10717255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hepatitis C--standard therapy].
    Rasenack JW
    Praxis (Bern 1994); 2000 Jun; 89(24):1049-55. PubMed ID: 10902461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.